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Abstract 
 
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with 
prominent motor symptoms. ALS patients may also manifest frontal behavior and cognitive 
decline, including impairment in facial emotion recognition. We aimed to investigate whether 
deficits in emotion recognition are associated with frontal behavior symptoms in ALS. 
Methods: We enrolled two groups of participants: 1) patients with probable or definite 
sporadic ALS (n= 21, 11 male/10 female; median age 62 years-old; median disease duration = 
3 years) and 2) age and education matched controls (n = 25, 18 male/11 female; median age 
61 years-old). The Facial Emotion Recognition Test (FERT) was applied to all participants. 
Patients underwent the Cambridge Behavior Inventory-Revised (CBI-R) and were classified 
according to the presence of frontal behavioral symptoms into two groups: ALS with no 
behavioral symptom (ALSns, n = 9) and ALS with at least one behavioral symptom (ALSbs, 
n = 12). 
Results: Apathy and mood symptoms were the most frequent neuropsychiatric symptoms in 
ALS. ALS patients performed worse than controls in the recognition of sadness (p<0.004). 
There was no difference between controls and ALSns for all FERT scores, but ALSbs had 
lower performance than controls in sadness (p<0.003). 
Conclusion: Emotion recognition deficit may be a marker of frontal behavior in ALS. 
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Introduction 
Besides prominent motor impairment, patients with amyotrophic lateral sclerosis (ALS) 
manifest cognitive and behavioral symptoms 1, 2. While executive impairment is the most 
common cognitive dysfunction in ALS 3, social cognition deficits have also been reported 1, 4, 
with decline in abilities such as theory of mind and emotional processing 1, 2. In this latter 
regard, deficits in recognition of facial emotion expressions are present in ALS 1, 5-10. ALS 
patients also exhibit behavioral symptoms, such as apathy, loss of empathy and personality 
changes 11, even at early stages of the disease and before motor symptoms 12. Cognitive and 
behavioral symptoms in ALS show great overlap with the presentation of behavioral variant 
frontotemporal dementia (bvFTD).  
However, it is not clear whether emotion recognition deficits in ALS occur in the absence of 
behavioral changes, as some of the previous studies in the field did not assess frontal 
behavioral symptoms with specific tools 6, 9, 13. It remains open the issue whether emotion 
recognition deficits can occur independently of frontal behavioral syndrome in ALS. 
Therefore, the aim of this exploratory study was to investigate the possible association 
between recognition of facial emotions and frontal behavioral symptoms (e.g., abnormal 
eating habits, apathy, stereotypical and motor behaviors, and other abnormal behaviors) in 
ALS. Taking into account that both emotion recognition and behavioral control rely on the 
integrity of prefrontal cortex, we hypothesized that deficits in the recognition of facial 
emotional expressions will be associated with frontal symptoms in ALS. 
 
Methods 
This study was conducted at the University Hospital of Federal University of Minas Gerais 
(Belo Horizonte, Brazil). The Local Ethics Committee approved the study, and all participants 
provided written informed consent.  
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We included two groups of subjects: 1) a consecutive series of patients diagnosed with 
probable or definite sporadic ALS (n = 21; 11 male/10 female; median age 62 years-old), 
according to Awaji’s criteria 14 and 2) healthy controls (n = 25; 18 male/11 female; median 
age 61 years-old), matched with the ALS group for age, sex and education level. The majority 
of patients (18/21) had spinal presentation. Table 1 presents demographical and clinical data. 
ALS patients were evaluated with a standardized clinical protocol described elsewhere 15. We 
did not include patients using non-invasive ventilation. Patients with severe psychiatric 
disorder (e.g. past diagnosis of bipolar disorder or schizophrenia) or with neurological disease 
other than ALS (e.g. past history of stroke, epilepsy) were not included. 
 Controls were recruited from the community on a voluntary basis. Controls were not included 
if they presented any of the following criteria: 1) history of neurological or psychiatric 
disorders; 2) cognitive complaints. We did not include controls who scored below norms on 
the Mini Mental Status Exam (MMSE) 16. 
All participants underwent a brief examination that included the MMSE and the Facial 
Emotion Recognition Test (FERT) derived from the Social and Emotional Assessment17, and 
the Hospital Anxiety and Depression scale (HAD). The HAD provides separate subscales for 
anxiety and depression. A score above 8 in each subscale is indicative of depression or 
anxiety 18. The FERT is composed by a panel of 35 pictures from Ekman’s portfolio 17, with 
seven different emotions (happiness, sadness, fear, disgust, surprise, anger, and neutral) 
presented five times each, as described elsewhere 17. Pictures are shown in a screen in a 
pseudo-randomized order. Importantly, labels of emotions (happiness, sadness, fear, disgust, 
surprise, anger, and neutral) are presented during the entire task to avoid impaired 
performance due to memory disorder. Participants pointed or verbally indicated their answers, 
which were computed by the investigator. ALS patients also underwent Verbal Fluency test 
(letter S in 1 minute) and the Portuguese version of the Cambridge Behavior Inventory-
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Revised (CBI-R) 19. The CBI-R assesses ten domains including functional abilities and 
cognitive, behavioral and psychiatric symptoms. Here we considered the four domains that 
identify bvFTD symptomatology (abnormal eating habits, apathy, stereotypical and motor 
behaviors, and abnormal challenging behaviors). Any particular behavior is rated on a scale 
from 0 (no impairment) to 4 (constant occurrence). Patients were then classified in terms of 
severity of impairment according to CBI-R score on each subscale: 0-25% was considered as 
mild; 26-50% as moderate; 51-75% as severe and higher than 75% as very severe 20. We 
classified ALS patients according to the presence of moderate to very severe bvFTD symptom 
(Figure 1A). Two subgroups were then established: one subgroup without any bvFTD feature 
(ALS without behavioral symptoms [ALSns]; n = 9[43%]) and ALS patients with at least one 
behavioral feature of bvFTD (ALS behavioral symptom [ALSbs], n = 12 [57%]). Of note, two 
patients (9%) in ALSbs group had impairment in three of these domains, then fulfilling 
criteria for bvFTD (Figure 1A). 
Statistical Analyses 
Descriptive statistics were performed to characterize the sample. Normality assumption was 
investigated with the Kolmogorov-Smirnov test. The statistical assumption of normality was 
refuted. Accordingly, non-parametric tests were adopted. Group comparisons were performed 
in two steps. We firstly used Mann-Whitney U test to compare continuous variables between 
healthy controls and ALS (total group). Secondly, Kruskal-Wallis test was employed for 
comparing continuous variables among groups (healthy controls, ALSns and ALSbs), and, 
when pertinent, Mann-Whitney U test was applied to perform two-by-two group comparisons. 
Chi-Square test was used for comparing categorical variables between groups.  After applying 
Bonferroni correction, the p-value was set at 0.005. Effect size was calculated with Pearson’r.  
Correlations among variables were performed using Spearman’s correlation test with 
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Bonferroni correction. We used the Statistical Package for Social Sciences (SPSS version 22) 
for all analyses. 
Results 
There was no difference among groups (healthy controls, ALSns and ALSbs) regarding 
sociodemographic variables (age, educational level and sex distribution). ALSns and ALSbs 
did not differ on disease duration. 
Most of ALS exhibited behavioral impairments according to CBI-R. Apathy was the most 
frequent behavioral disorder (48% of patients), with moderate to very severe intensity in all of 
them (Figure 1B).  
Patients had higher scores than controls on HAD-anxiety and HAD-depression scales (Table 
1). Moreover, nine patients (9/21, 43%) scored above cut-off on the anxiety measure, and 
seven patients (7/21, 33%) scored above cut-off on the depression measure, indicating 
clinically relevant symptoms. Four ALSbs patients had both depression and apathy and four 
patients (including one patient with ALS-bvFTD) had both anxiety and apathy. Two ALSbs 
patients (including one patient with ALS-bvFTD) had depression, anxiety and apathy. 
Compared to controls, ALS patients had lower performance on cognitive screening measures, 
the MMSE (p<0.02, r = 0.35) (Table 1). Due to motor and/or speech impairment, 11 out 21 
patients (52%) of patients did not complete the entire MMSE. Without these patients with 
incomplete MMSE, there was no difference on the MMSE between the ALS and the control 
groups.  
Patients (total group) did not differ from controls on the total score on the FERT and on all 
Ekman Faces Test categories, except sadness (p<0.004, r = 0.43), with patients performing 
worse than controls (Table 1). 
There was no difference between controls and ALSns for all FERT scores, while ALSbs had 
lower performance than controls in sadness (p<0.003, r = 0.49). We re-ran comparison 
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between controls and ALSbs without ALS-bvFTD patients (n =2) and there was a trend 
(p<0.02) for the same difference on the recognition of sadness. There was no difference 
between ALS subgroups (ALSbs vs ALSns) for all demographical, clinical and cognitive 
measures, including FERT (Table 1). 
No correlation was found between FERT and MMSE in the ALS group. Similarly, there was 
no correlation between FERT and verbal fluency. There was no statistically significant 
correlation between FERT (Total Score) and HAD-anxiety and HAD-depression scales.  
 
Discussion 
This study investigated the potential association between emotion recognition and behavioral 
symptoms in ALS. Apathy was the most prominent neuropsychiatric syndromes, which is in 
line with previous studies 11. Lack of motivation, changes in eating habits, abnormal behavior, 
stereotypical and motor behavior are observed in bvFTD and are considered as core 
diagnostic criteria for this condition 21. In our sample, 57% of ALS patients had at least one of 
these domains affected and two patients (9%) had impairment in three of these domains, then 
fulfilling criteria for bvFTD. This finding is in agreement with previous reports of estimated 
prevalence of bvFTD in up to 15% ALS patients 2, 4. These findings support the concept of 
frontotemporal spectrum disorder in ALS 4. 
Depressive symptoms were also frequent as 33% of patients had clinically relevant depressive 
symptoms according to HAD-depression. Depressive symptoms may be observed in bvFTD 22 
and are commonly observed in ALS 23-25. Here we found that depressive or anxiety symptoms 
may overlap with apathy and other bvFTD features in ALS. Apathy, challenging behavior and 
other neuropsychiatric features co-occur in frontotemporal lobar degeneration syndromes 26. It 
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is unclear why there is association between depression, anxiety and bvFTD features in ALS. 
Further research is warranted to clarify this question.   
Emotion recognition did correlate neither with MMSE nor with an executive task (verbal 
fluency). Actually, there was no correlation between FERT and scores on psychiatric scales 
for anxiety (HAD-A) and depression (HAD-D). Social cognition impairment in ALS was not 
associated with depressive symptoms in a recent meta-analysis 1. Moreover, emotion 
recognition did correlate neither with MMSE nor with an executive task (verbal fluency). 
These findings suggest that emotion recognition impairment in ALS does not reflect neither 
mood disorders nor deficits in general cognition/executive functions. This pattern is similar to 
the one seen in bvFTD, but not in other neurodegenerative diseases such as Alzheimer’s 
disease in which social cognition decline is mediated by executive dysfunction 27.  
ALS (total group) performed worse than controls in recognition of sadness. Functional 
neuroimaging studies in healthy subjects found that the processing of sad faces is related to 
the activation on amygdala, insula, thalamus and lingual gyrus 28. Interestingly, these regions 
are progressively affected during the spread of 43kDa TAR DNA binding protein (TDP-43)-
pathology through the clinical stages of ALS 29, 30. A recent study investigated metabolic 
correlates of processing emotional faces in ALS patients and reported increased metabolism 
in the right inferior frontal gyrus and decreased activity in the hippocampi during processing 
sad faces 5. In sum, impairment in sadness recognition in ALS suggests pathological 
involvement of insula, limbic structures and prefrontal regions during the course of the 
disease, but neuropathological studies are warranted to confirm this hypothesis. Deficits in 
other emotions such as disgust and surprise have also been reported 1. 
Even though it is well established that ALS patients have impairments in emotion recognition 
1, some studies in the field did not control for FTD-related behavioral symptoms 6, 9, 13. 
Interestingly, after categorizing ALS patients into those with (ALSbs) or without (ALSns) 
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frontal features, only the subgroup with coexisting behavioral impairment (ALSbs) was 
impaired in emotion recognition, as previously reported7. Taken together, these results 
suggest that deficits in emotion recognition co-occur with frontal behavioral symptoms in 
ALS.  
The study has some caveats that should be considered. The small sample size may explain 
some of the lack of associations found and may limit the generalizability of the results. 
Moreover, we did not perform neuroimaging analyses which would be of value for 
understanding the neural basis of emotional recognition in ALS. Despite these limits, our 
results highlight the cognitive and neuropsychiatric heterogeneity of ALS and suggest that 
emotion recognition deficits may be a marker of frontal behavior in ALS.  
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Table 1: Demographic, clinical and neuropsychological data for participants 
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 Controls (n = 25) ALS (n = 21) ALS no behavioral symptoms (n = 9) ALS behavioral (n = 12) 
Characteristic Median P25-P75 Median P25-P75 p value vs controls 
(M-W test) 
r Median P25-P75 p value vs controls 
(M-W test) 
r Median P25-P75 p value vs controls 
(M-W test) 
r 
Age (years) 61 54-65 62 56-66.5 0.740 0.05 64 49-66.5 0.969 0.10 61 (58-66) 0.666 0.07 
Schooling (Years  of Education) 5 4-11 5 1-3.5 0.787 0.04 6 4-9.5 0.848 0.03 5 (4-10) 0.597 0.09 
Sex (Male/Female) 14/11 NA 14/11 NA 0.806 § NA 5/4 NA 0.982 § NA 6/6 NA 0.732 § NA 
Disease Duration (years) NA NA 3 1-3.5 NA NA 3 1-3.5 NA NA 3 (1-4) NA NA 
HAD Anxiety (HAD-A) 4 2-6 8 * 4-13* 0.002 0.47 6 4-12 0.066 0.32 8 * 5-13* 0.001 0.55 
HAD Depression (HAD-D) 2 1-5 6 * 4-10* 0.002 0.46 6 3-11 0.055 0.34 7 * 4-11* 0.003 0.48 
MMSE ( /30) 26 25-28 24 20-27 0.018 0.35 25 23-27 0.130 0.27 23 18-28 0.030 0.36 
Fluency Letter S NA NA 7 5-9 NA NA 7 6-10 NA NA 6 1-9 NA NA 
FERT - Total score  (   /35) 23 21-26 21 17-26 0.147 0.21 23 17-28 0.730 0.06 19 17-26 0.066 0.30 
FERT - Happiness (  / 5) 5 5-5 5 5-5 0.571 0.08 5 5-5 0.848 0.06 5 5-5 0.761 0.09 
FERT - Surprise (  / 5) 4 2-4 3 2-4 0.640 0.07 4 2-5 0.908 0.02 3 2-5 0.597 0.09 
FERT - Disgust (  / 5) 3 3-4 4 3-5 0.255 0.17 4 3-5 0.419 0.15 4 3-5 0.378 0.16 
FERT - Fear (  / 5) 2 1-3 2 1-3 0.751 0.05 2 1-4 0.565 0.10 2 1-3 1.0 0.01 
FERT - Anger (  / 5) 3 3-4 2 1-4 0.037 0.31 3 2-4 0.442 0.14 2 1-3 0.021 0.39 
FERT - Sadness (  / 5) 3 3-4 2* 1-3* 0.004 0.43 3 2-4 0.140 0.27 2 * 1-3* 0.003 0.49 
FERT - Neutral (  / 5) 4 3-5 3 1-4 0.170 0.20 4 2-5 0.848 0.04 2 1-4 0.077 0.30 
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Table 1  
Legend 
ALS = Amyotrophic Lateral Sclerosis; FERT = facial emotion recognition test; HAD = 
Hospital Anxiety and Depression Scale; MMSE = Mini-Mental State Exam; M-W: Mann-
Whitney; NA = Not applicable; P25 = 25th Percentile; P75 = 75th Percentile. 
*  p<0.005 vs controls (Mann-Whitney test) 
§ p value for Chi-square test. 
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Figure 1 
Legend 
A. Proportion of patients in the Amyotrophic Lateral Sclerosis (ALS) – Frontotemporal 
dementia (FTD) spectrum. B. Behavioral symptoms measured by the Cambridge Behavioral 
Inventory Revised (CBI-R) in patients with ALS. 
S&M behavior = Stereotypical and motor abnormal behavior 
 
 
 
 
 
 
 
